SLC29A1

Across TCGA pan-cancer cohorts, SLC29A1 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of SLC29A1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where SLC29A1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SLC29A1 is over-expressed in tumor, although a few such as COAD and HNSC show the opposite, repressed pattern.

CCRCC, COAD, and HNSC are the cancer types where SLC29A1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC29A1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	IV	+0.928	<.001	11	view →
COAD	Female	All	−0.588	<.001	9	view →
HNSC	Male	All	−0.422	.002	8	view →
LUAD	Male	II,III,IV	−0.924	<.001	7	view →
PDAC	All	All	−1.012	.016	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

SLC29A1–CCRCC

Open the CCRCC breakdown →